Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Celltrion Nearly Triples Production Capability For Biosimilars In Anticipation Of Global Launches

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's biosimilar front-runner Celltrion, Inc. will begin production at a new 90,000-liter manufacturing plant Oct. 5 located at its main plant in Incheon City

You may also be interested in...



Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma

SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma

Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma

SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma

Korea's Hanwha Chemical Leads With Enbrel Biosimilar - BIO Korea

Merck will develop and commercialize the biosimilar form of Enbrel - HD203 - in all markets except Korea and Turkey, where Hanwha retained marketing rights.

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip
Tags:
Latest Headlines

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Falling Sales Force New Priorities At Roche

How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies

IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf

See All
UsernamePublicRestriction

Register

SC079054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By